外交部:中國2021年將對外提供20億劑疫苗
格隆匯11月12日丨外交部記者會上,有記者提問:全球已接種約70億劑疫苗,受中國疫苗帶動,智利、柬埔寨接種率已達79%、77%,高於美歐等發達國家。中方對此有何評論?汪文斌表示:中國克服自身人口基數巨大、疫苗供應緊張的現實困難,迄今已向世界110多個國家和國際組織提供了超過17億劑的疫苗,2021年全年將努力對外提供20億劑。中國已向“新冠疫苗實施計劃”供應超過了7000萬劑疫苗,並捐贈1億美元,還同30多個國家發起了“一帶一路”疫苗合作夥伴關係倡議,同19個發展中國家開展疫苗聯合生產。目前,中國已成爲世界上對外提供新冠疫苗最多的國家,發展中國家迄今獲得的疫苗大多數來自中國。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.